Chinese consensus on gastroesophageal reflux disease (GERD):* October 2006, Sanya, Hainan Province, China

Journal of Digestive Diseases

Volumn 8, Issue 3, 2007, Pages 162-169

  Lin, San Ren ^a   Xu, Guo Ming ^b   Hu, Pin Jin ^c   Zhou, Li Ya ^a   Chen, Min Hu ^c   Ke, Mei Yun ^d   Yuan, Yao Zong ^e   Fang, Dian Chun ^f   Xiao, Shu Dong ^e  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Barrett's esophagus; Consensus; Diagnosis; Erosive esophagitis; Gastroesophageal reflux disease; Non erosive reflux disease; Treatment

Indexed keywords

EID: 84876067570     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2007.00298.x     Document Type: Article

References (62)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
2. Armstrong D, Marshall JK, Chiba N et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults-update 2004. Can J Gastroenterol 2005; 19: 15-35.
3. Guidelines for the diagnosis and management of Barrett's columnar lined oesophagus. A report of the Working Party of the British Society of Gastroenterology. Accessed 17 January 2006. Available from URL: http://www.bsg.org.uk
4. DeVault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.
5. Fock KM, Talley N, Hunt R et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19: 357-67.
6. Fass R, Ofman JJ. Gastroesophageal reflux disease-should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-9.
7. Armstrong D, Bennett JR, Blum AL et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
8. Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 29-37.
9. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
10. Bretagne JF, Richard-Molard B, Honnorat C, Caekaert A, Barthelemy P. Gastroesophageal reflux in the French general population. National survey of 8000 adults. Presse Med 2006; 35 (1 Pt 1): 23-31.
11. Ponce J, Vegazo O, Beltran B et al. Prevalence of gastro-oesophageal reflux disease in Spain and associated factors. Aliment Pharmacol Ther 2006; 23: 175-84.
12. Farup C, Kleinman L, Sloan S et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161: 45-52.
13. Schwenkglenks M, Marbet UA, Szucs TD. Epidemiology and costs of gastroesophageal reflux disease in Switzerland: a population-based study. Soz Praventivmed 2004; 49: 51-61.
14. Fujiwara Y, Higuchi K, Watanabe Y et al. Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J Gastroenterol Hepatol 2005; 20: 26-9.
15. Cho YS, Choi MG, Jeong JJ et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea. Am J Gastroenterol 2005; 100: 747-53.
16. Lim SL, Goh WT, Lee JM et al. Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol 2005; 20: 995-1001.
17. Chen M, Xiong L, Chen H et al. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China. Scand J Gastroenterol 2005; 40: 759-67.
18. Pan GZ, Xu GM, Ke MY et al. Epidemiological study of symptomatic gastroesophageal reflux disease in China: Beijing and Shanghai. Chin J Dig Dis 2000; 1: 2-8.
19. Goh KL, Chang CS, Fock KM, Ke M, Park HJ, Lam SK. Gastro-oesophageal reflux disease in Asia. J Gastroenterol Hepatol 2000; 15: 230-8.
20. Kang JY, Tay HH, Yap I, Guan R, Lim KP, Math MV. Low frequency of endoscopic esophagitis in Asian patients. J Clin Gastroenterol 1993; 16: 70-3.
21. Maekawa T, Kinoshita Y, Okada A et al. Relationship between severity and symptoms of reflux oesophagitis in elderly patients in Japan. J Gastroenterol Hepatol 1998; 13: 927-30.
22. Yi SY, Lee SK, Kim MH et al. Epidemiologic study of reflux esophagitis in general health screening people. Korean J Med 1994; 46: 514-20.
23. Li ZS, Xu XR, Xu GM et al. Clinical characteristics of reflux esophagitis in Chinese population. Chin J Dig Endosc 2005; 22: 315-8 (in Chinese).
24. Hu ZY, Zhou LY, Lin SR, Xue Y. Analysis of clinical characteristics in 2088 patients with reflux esophagitis during past decade. Chin J Dig 2005; 25: 717-9 (in Chinese).
25. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med 1995; 27: 67-70.
26. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000; 14: 1589-94.
27. Haque M, Wyeth JW, Stace NH, Talley NJ, Green R. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J 2000; 113: 178-81.
28. Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Pharmacol Ther 2005; 21: 821-7.
29. Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, Locke GR 3rd, Rodriguez-Artalejo F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factorsin a Spanish population. Aliment Pharmacol Ther 2004; 19: 95-105.
30. Wong WM, Lai KC, Lam KF et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003; 18: 595-604.
31. Locke GR, 3rd Talley NJ, Fett SL, Zinsmeister AR, Meltor LJ 3rd. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999; 106: 642-9.
32. Zhou LY, Lin SR, Ding SG et al. A mass survey on the morbidity of erosive reflux esophagitis in farmers of Sandong province. Chin J Dig Endosc 2005; 22: 101-3 (in Chinese).
33. Wang JH, Luo JY, Gong J, Tao M. Reflux esophagitis epidemiology and clinical study. Chin J Dig Endosc 2000; 17: 345-8 (in Chinese).
34. Castell DO, Murray JA, Tutuian R, Orlando RC, Arnold R. Review article. The pathophysiology of gastro-oesophageal reflux disease-oesophageal manifestations. Aliment Pharmacol Ther 2004; 20 (Suppl 9): 14-25.
35. Cremonini F, Talley NJ. Review article: the overlap between functional dyspepsia and irritable bowel syndrome-a tale of one or two disorders? Aliment Pharmacol Ther 2004; 20 (Suppl 7): 40-9.
36. Fang XC, Ke MY, Pan GZ et al. Functional gastrointestinal disease: overlapping symptoms or a disorder? Analysis of data on a whole group, stratified and randomized epidemiological survey. Basic Clin Med 2005; 25 (Suppl): 226 (in Chinese).
37. Xu GM, Fang YQ, Cheng NN et al. Diagnostic value of Omeprazole test in gastroesophageal reflux diseases. Chin J Dig 2002; 22: 7-10.
38. Wang K, Duan LP, Chen H, Xia ZW, Lin SR. Comparison of esophageal acid exposure characteristics between reflux oesophagitis and non-erosive reflux disease. Chin J Intern Med 2005; 44: 5-8.
39. Xue Y, Zhou LY, Lin SR, Huang YH. The application of high-resolution endoscopy in non-erosive reflux diseases. Chin J Intern Med 2006; 45: 389-92.
40. Liang XY, Lan Y, Jia YB et al. Clinical characteristics of esophageal acid exposure, and esophageal pressure and Helicobacter pylori infection in reflux esophagitis and non-erosive reflux disease. Chin J Dig Endosc 2006; 23: 11-4 (in Chinese).
41. Xu XR, Li ZS, Xu GM, Zou DW, Yin N, YeP. The role of duodenogastroesophageal reflux in gastroesophageal reflux disease. Chin J Intern Med 2004; 43: 269-71 (in Chinese).
42. Sun XH, Ke MY, Wang ZF et al. Roles of diaphragmatic crural barrier and esophageal body clearance in patients with gastroesophageal reflux disease. Acta Academiae Med Sinicae 2002; 24: 289-93 (in Chinese).
43. Liu HM, Ke MY, Wang ZF et al. Esophageal motor pattern during fasting and postprandial states in non-severe reflux esophagitis. Chin J Gastroenterol 1997; 2: 19-22 (in Chinese).
44. Sun XH, Ke MY, Wang ZF, Fang XC, Liu XH. Evaluation of the factors of long-term treatment in patients with gastroesophageal reflux disease. Chin J Pract Intern Med 2004; 24: 476-8 (in Chinese).
45. Kuster E, Ros E, Toledo-Pimentel V et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994; 35: 8-14.
46. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-45.
47. Galmiche JP, Clouse RE, Balint A et al. Functional esophageal disorders. Gastroenterology 2006; 130: 1459-65.
48. Sharma P, McQuaid K, Dent J et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30.
49. Egger K, Werner M, Meining A et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut 2003; 52: 18-23.
50. Paris Workshop on Columnar Metaplasia in the Esophagus and the Esophagogastric Junction, Paris, France, December 11-12 2004. Endoscopy 2005; 37: 879-920.
51. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476-80.
52. Rugge M, Correa P, Dixon MF et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000; 24: 167-76.
53. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus-the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998; 93: 1033-6.
54. Richter JE. Short segment Barrett's esophagus: ignorance may be bliss. Am J Gastroenterol 2006; 101: 1183-5.
55. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004; 39: 1175-9.
56. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol, 1989; 24: 401-6.
57. Paul K, Redman CM, Chen M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther 2001; 15: 1571-7.
58. Ciociola AA, Pappa KA, Sirgo MA. Nonprescription doses of ranitidine are effective in the relief of episodic heartburn. Am J Ther 2001; 8 (6): 399-408.
59. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 18: CD002095.
60. Bour B, Staub JL, Chousterman M et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 2005; 21: 805-12.
61. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med 2003; 114: 1-5.
62. Galmiche JP, Bruley des Varannes S. Endoluminal therapies for gastro-oesophageal reflux disease. Lancet 2003; 361: 1119-21.